Acorda Therapeutics clinical trials
The registry lists 53 studies whose lead sponsor is Acorda Therapeutics or one of 3 companies grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 23, 2021.
Our grouping of 4 registry names, not the registry’s. See them and correct one ↓
- 53studies on the registry
- 0open to participants now
What it is testing
The drugs Acorda Therapeutics’ studies test, most studies first; none is open now — 10 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 53 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 07
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 915
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 7 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Acorda Therapeutics.
- Acorda Therapeutics38 studiesSame company
Something wrong?
- Biotie Therapies Inc.10 studies →Acquired — became part of Acorda Therapeutics, Apr 11, 2016 · source ↗
Something wrong?
- Biotie Therapies Corp.3 studies →Acquired — became part of Acorda Therapeutics, Apr 11, 2016 · source ↗
Something wrong?
- 2 studies →
Focus areas
Conditions Acorda Therapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 53. Browse all 53 →
- A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG TrialCompletedNCT01839279Phase 2
- Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord InjuryCompletedNCT00041717Phase 3
- Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesCompletedNCT02242487Phase 3
- Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)CompletedNCT03887884Phase 1
- Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesCompletedNCT02240030Phase 3
- Randomized Safety Study of CVT-301 Compared to an Observational Control GroupCompletedNCT02352363Phase 3
- Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.TerminatedNCT03051607Phase 3
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted after Biotie Therapies Inc. became part of Acorda Therapeutics
- SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)CompletedNCT02258152Phase 2
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's PatientsTerminatedNCT02453386Phase 3
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)CompletedNCT00595231Phase 2
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.TerminatedNCT02422940Phase 3
- Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing OffCompletedNCT01283594Phase 2/3
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- AC105 in Patients With Acute Traumatic Spinal Cord InjuryTerminatedNCT01750684Phase 2
- Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)TerminatedNCT02474407Phase 2
- Study of Oral Fampridine-SR in Multiple SclerosisCompletedNCT00127530Phase 3
- An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a RelapseCompletedNCT02398461Phase 1
- Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent VolunteersCompletedNCT00656357Phase 1/2
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug UsersTerminatedNCT03200080Phase 1
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted after Biotie Therapies Inc. became part of Acorda Therapeutics
- Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF EpisodesCompletedNCT01777555Phase 2
- An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.TerminatedNCT02316847Phase 2
- A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.CompletedNCT02271217Phase 3
- A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation PowderCompletedNCT02905227Phase 1
- Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of TozadenantTerminatedNCT03212313Phase 1
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted after Biotie Therapies Inc. became part of Acorda Therapeutics
- Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord InjuryCompletedNCT01683838Phase 3
- Study to Evaluate SYN115 in Parkinson's DiseaseCompletedNCT00605553Phase 2
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled TozadenantCompletedNCT02240290Phase 1
Sponsor listed in the registry: Biotie Therapies Inc. · First submitted before Biotie Therapies Inc. became part of Acorda Therapeutics
- Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" EpisodesCompletedNCT01617135Phase 2
- A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure EpisodeCompletedNCT01417078Phase 2
- A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)CompletedNCT02807675Phase 1
- A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) TabletsCompletedNCT02812394Phase 1
- A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking AdultsCompletedNCT02633839Phase 1
- A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart FailureCompletedNCT01944683Phase 1
- A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult VolunteersCompletedNCT02663999Phase 1
- A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With AsthmaCompletedNCT02633007Phase 1
- Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy AdultsCompletedNCT02609945Phase 1
- Study of Fampridine-SR Tablets in Multiple Sclerosis PatientsCompletedNCT00483652Phase 3
- A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic StrokeCompletedNCT01605825Phase 2
- An Intravenous Infusion Study of rHIgM22 in Patients With Multiple SclerosisCompletedNCT01803867Phase 1
- Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart FailureCompletedNCT01258387Phase 1
- Safety and Tolerability of Dalfampridine in Subjects With Cerebral PalsyCompletedNCT01468350Phase 1
- An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)CompletedNCT01535664
- Study of Fampridine-ER Tablets in Patients With Multiple SclerosisCompletedNCT01328379Phase 3
- Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral PalsyTerminatedNCT01405950Phase 1
- Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal ImpairmentCompletedNCT01316055Phase 1
- Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00654927Phase 3
- Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 TrialCompletedNCT00649792Phase 3
- Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 TrialCompletedNCT00648908Phase 3
- BTT-1023 in Rheumatoid ArthritisCompletedNCT00851240Phase 1
Sponsor listed in the registry: Biotie Therapies Corp. · First submitted before Biotie Therapies Corp. became part of Acorda Therapeutics
- Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple SclerosisCompletedNCT00053417Phase 2
- Safety and Pharmacokinetics of ELB353 in Healthy MenCompletedNCT00977886Phase 1
Sponsor listed in the registry: Biotie Therapies Corp. · First submitted before Biotie Therapies Corp. became part of Acorda Therapeutics